PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Immatics (IMTX) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside [Yahoo! Finance]
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate [Yahoo! Finance]
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot [Seeking Alpha]